Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 10.15 0.01 (0.1%) Market Cap: 1.19 Bil Enterprise Value: 1.03 Bil PE Ratio: 0 PB Ratio: 6.33 GF Score: 38/100
Back to the Transcripts List

Q2 2024 Arcutis Biotherapeutics Inc Earnings Call Transcript

Aug 14, 2024 / 08:30PM GMT
Release Date Price: $9.58 (-3.72%)

Key Points

Positve
  • Strong revenue growth with net revenues of $30.9 million, up 547% year-over-year and 43% quarter-over-quarter.
  • Successful launch and positive reception of ZORYVE cream and foam for psoriasis and seborrheic dermatitis.
  • Expansion into the primary care and pediatric space through a co-promotion deal with Kowa Pharmaceuticals.
  • Improved gross-to-net percentages, with ZORYVE cream and foam achieving high coverage rates.
  • Favorable renegotiation of debt terms with SLR, providing improved financial flexibility and reduced interest rates.
Negative
  • High SG&A expenses, which increased to $58.2 million, impacting profitability.
  • Continued reliance on prescription growth for revenue, with potential moderation in gross-to-net improvements.
  • Uncertainty around the timing of meaningful revenue contributions from the primary care and pediatric expansion.
  • Challenges in achieving broad Medicare and Medicaid coverage, with ongoing negotiations required.
  • Potential delays in pipeline developments, with specific timelines for new indications and products still uncertain.
Operator

Hello, and thank you for standing by. Welcome to our Arcutis Biotherapeutics Q2 2024 earnings call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to turn the call over to Latha Vairavan, Vice President, Finance, and Investor Relations. You may begin.

Latha Vairavan
Arcutis Biotherapeutics Inc - Vice President, Finance and Head of Investor Relations

Thank you, Tywanda. Good afternoon, everyone, and thank you for joining us today to review our second quarter 2024 financial results and business update. Slides for today's call are available on the Investor section of the Arcutis website. On the call today are Frank Watanabe, President, and CEO; Patrick Burnett, Chief Medical Officer; Todd Edwards, Chief Commercial Officer; and David Topper, Chief Financial Officer.

I would like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.